SCHEMBL498577

SCHEMBL498577

O=C(O)c1ccc(-c2ccc(-c3cccs3)s2)s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
KDM4E B2RXH2 4/20 0.69
LMNA P02545 2/20 0.69
GAA P10253 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
GLA P06280 1/20 0.69
MAPT P10636 1/20 0.69
RAB9A P51151 4/20 0.67
NPC1 O15118 3/20 0.67
HPGD P15428 3/20 0.67
MEN1 O00255 2/20 0.67
POLB P06746 2/20 0.67
KMT2A Q03164 2/20 0.67
TP53 P04637 1/20 0.67
NFKB1 P19838 1/20 0.67
MAPK1 P28482 1/20 0.67
CASP1 P29466 1/20 0.67
CASP7 P55210 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280023 1.00 ALDH1A1 (0.69) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL1761399 0.98 ALDH1A1 (0.71) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL27816591 0.86 RAB9A (0.69) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL7870469 0.85 ALDH1A1 (0.89) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL2615879 0.84 MEN1 (0.63) ALDH1A1KDM4EGAARAB9AHPGD
SCHEMBL2615881 0.84 MEN1 (0.63) ALDH1A1KDM4EGAARAB9AHPGD
SCHEMBL14854089 0.84 ALDH1A1 (0.67) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL8572753 0.84 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL498669 0.84 ALDH1A1 (0.67) ALDH1A1KDM4ELMNAGAAL3MBTL1
SCHEMBL20181377 0.84 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
US-20200290033-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-09-17 US disclosed
US-10717072-B2 Functionalized zinc oxide nanoparticles for photocatalytic water splitting COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-07-21 US disclosed
US-20160318010-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-11-03 US disclosed
US-20160318010-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-11-03 US disclosed
US-20160318010-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-11-03 US disclosed
EP-3083491-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING Council of Scientific and Industrial Research (IN) 2016-10-26 EP disclosed
US-9226917-B2 Photodynamic therapy for conditions of the eye VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2016-01-05 US disclosed
WO-2015092816-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-06-25 WO disclosed
WO-2015092816-A1 FUNCTIONALIZED ZINC OXIDE NANOPARTICLES FOR PHOTOCATALYTIC WATER SPLITTING COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-06-25 WO disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085213-A2 SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
US-5753692-A PLANT EXTRACTS, IMMUNOSTIMULANTS TREATING IMMUNODEFICIENCY DISEASES INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1998-05-19 US disclosed
US-5747525-A ANTITUMOR AGENTS OF OLIGOMERS OF THIOPHENE INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1998-05-05 US disclosed
US-5602170-A ADMINISTERING ANTIIFLAMMATORY AGENT INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 1997-02-11 US disclosed
US-5180838-A Terthienyl compounds as insecticides HER MAJESTY THE QUEEN AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1993-01-19 US disclosed
US-5045563-A Terthienyl Compound HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1991-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA ALDH1A1 371/4885KDM4E 3097/4885LMNA 3268/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 ALDH1A1 794/4885KDM4E 4361/4885LMNA 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.